In a bid to enter new therapeutic areas and expand its offerings, Covis Group has acquired AMAG Pharmaceuticals for US$498 M. The deal gives Covis access to AMAG’s marketed portfolio which comprises of Makena® (hydroxyprogesterone) and Feraheme® (ferumoxytol), as well as a Phase II asset ciraparantag. Four days after the Covis deal was announced, the FDA’s Center for Drug Evaluation and Research proposed to withdraw Makena from the market after it failed to show clinical benefit in a post-market study.